Drug resistant TB – latest developments in epidemiology, diagnostics and management

•DR- and MDR-TB are more frequent in contacts and patients previously treated.•Whole genome sequencing, rapid, consistent and sensitive, is very useful in outbreaks•RR/MDR-TB requires treatment with ≥4 drugs for 6–24 months.•An all oral shorter WHO course is now recommended for the treatment of RR-T...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of infectious diseases Ročník 124; s. S20 - S25
Hlavní autori:	Tiberi, Simon, Utjesanovic, Natasa, Galvin, Jessica, Centis, Rosella, D'Ambrosio, Lia, van den Boom, Martin, Zumla, Alimuddin, Migliori, Giovanni Battista
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Ltd 01.11.2022 Elsevier
Predmet:	Active TB drug safety monitoring (aDSM) Adherence Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use BPaL Drug susceptibility testing (DST) Drug-resistant TB (DR-TB) Extensively Drug-Resistant Tuberculosis - diagnosis Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - epidemiology Humans Isoniazid - therapeutic use Mycobacterium tuberculosis - genetics Rehabilitation Rifampin - therapeutic use Treatment Guidelines Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Video Observed Therapy (VOT) WHO shorter oral regimen Adherence Treatment Guidelines BPaL Video Observed Therapy (VOT) WHO shorter oral regimen Rehabilitation Drug-resistant TB (DR-TB) Drug susceptibility testing (DST) Active TB drug safety monitoring (aDSM)
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!